In a study on a sample of 321 adenocarcinomas, Kim et al. found HER2 receptor protein expression most often in papillary carcinomas (50%), which differs from our results where papillary-predominant tumours did not show HER2 overexpression. This evidence concerns the gene ERBB2 and thyroid gland papillary carcinoma.